Sarepta Therapeutics (SRPT) R&D In Process (2019)
Sarepta Therapeutics' quarterly R&D In Process came in at $173.2 million in Q2 2019.
Sarepta Therapeutics has reported R&D In Process for 1 years, with the latest figure at $173.2 million in Q2 2019.
- For the quarter ending Q2 2019, R&D In Process changed N/A year-over-year to $173.2 million; the trailing twelve-month figure through Dec 2019 stood at $173.2 million (changed N/A YoY), and the FY2019 full-year result was $173.2 million, changed N/A from the prior year.
- R&D In Process for Q2 2019 stood at $173.2 million.
- The five-year high for R&D In Process was $173.2 million in Q2 2019, with the low at $173.2 million in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 500,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 101.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 173.24 Mn |